Background The poor physical health of people with mental illness is a multifaceted,
transdiagnostic, and global problem. People with mental illness have an increased risk of …

People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Background Emraclidine is a novel, brain-penetrant, highly selective M4 receptor positive
allosteric modulator in development for the treatment of schizophrenia. We aimed to …

According to current evidence and guidelines, continued antipsychotic treatment is key for
preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based …

Objective: In a phase 3 randomized double-blind placebo-controlled study, the authors
investigated the efficacy and safety of 42 mg/day of lumateperone in patients with bipolar I or …

Cancer stem cells (CSCs) contribute to the initiation, recurrence, and metastasis of cancer;
however, there are still no drugs targeting CSCs in clinical application. There are several …

The literature on non-genetic peripheral biomarkers for major mental disorders is broad, with
conflicting results. An umbrella review of meta-analyses of non-genetic peripheral …

Objective: This study used meta-analysis to assess disparities in cardiovascular disease
(CVD) screening and treatment in people with mental disorders, a group that has elevated …

Clozapine, a dibenzodiazepine developed in 1961, is a multireceptorial atypical
antipsychotic approved for the treatment of resistant schizophrenia. Since its introduction, it …

Background: Successful treatment of major depressive disorder (MDD) can be challenging,
and failures (" treatment-resistant depression"[TRD]) are frequent. Steps to address TRD …